Condition: Gastroesophageal Junction Adenocarcinoma (Siewert II-III) · Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
This project intends to study the efficacy and safety of camrelizumab combined with chemotherapy followed by radiotherapy in the perioperative treatment of AEG.
This description comes directly from the study's public registry record.
Yong Li, chief physician · 010-87788052 · liyongdoctor@126.com
Geng Shu Gao, Vice president · 010-87788052 · gaoshugeng1susar@sina.com
Always discuss trial participation with your own doctor first.
| Shugeng Gao | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06163729